Evidence map›Paper›PMID 36778546›Full record

ArticleFrontiers in public health2023

Effect of a modified regimen on drug-sensitive retreated pulmonary tuberculosis: A multicenter study in China.

Qiping Ge, Yan Ma, Lijie Zhang, Liping Ma, Caiyan Zhao, Yuhui Chen, Xuerui Huang, Wei Shu, Shengyu Chen, Fei Wang and 27 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors at 9 institutions in 1 country.

Qiping GeDepartment of Tuberculosis, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Yan MaInstitute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China.
Lijie ZhangDepartment of Tuberculosis, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Liping MaDepartment of TB Control, Henan Center for Disease Control and Prevention, Zhengzhou, Henan, China.
Caiyan ZhaoDepartment of Tuberculosis, Haerbin Chest Hospital, Haerbin, China.
Yuhui ChenDepartment of Outpatients, Center for Tuberculosis Control of Guangdong Province, Guangzhou, Guangdong, China.
Xuerui HuangDepartment of Tuberculosis, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Wei ShuDepartment of Tuberculosis, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Shengyu ChenDepartment of Outpatients, Center for Tuberculosis Control of Tianjin, Tianjin, China.
Fei WangDepartment of TB Control, Zhejiang Center for Disease Control and Prevention, Hangzhou, Zhejiang, China.
Bo LiDepartment of Outpatients, Beijing Center for Disease Control and Prevention, Beijing, China.
Xiqin HanDepartment of Tuberculosis, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Lian ShiDepartment of Tuberculosis, Shenyang Chest Hospital, Shenyang, Liaoning, China.
Xin WangDepartment of TB Control, Heilongjiang Center for Disease Control and Prevention, Haerbin, Heilongjiang, China.
Youlun LiDepartment of Tuberculosis, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Shangpeng YangDepartment of Tuberculosis, Jingzhou Hospital for Infectious Diseases, Jingzhou, Hubei, China.
Wenli CaoDepartment of Infectious Disease, Beijing Geriatric Hospital, Beijing, China.
Qianying LiuDepartment of Tuberculosis, 8th Medical Center, PLA General Hospital, Beijing, China.
Ling ChenDepartment of Respiratory and Critical Care Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
Chao WuDepartment of Tuberculosis, The 3rd People's Hospital of Zhenjiang, Zhenjiang, Jiangsu, China.
Bing OuyangDepartment of Tuberculosis, Kunming 3rd People's Hospital, Kunming, Yunnan, China.
Furong WangDepartment of Medicine, The 4th Hospital of Inner Mongolia Autonomous Region, Huhehaote, China.
Po LiDepartment of Tuberculosis, The 3rd Hospital of Baotou, Baotou, China.
Xiang WuDepartment of Tuberculosis, Jingmen Center for Disease Control and Prevention, Jingmen, Hubei, China.
Xiue XiDepartment of Tuberculosis, The First Affiliated Hospital of Xinxiang Medical College, Xinxiang, China.
Xueyan LengDepartment of Tuberculosis, The 3rd Hospital of Qinhuangdao, Qinhuangdao, Hebei, China.
Haiqing ZhangDepartment of Tuberculosis, Xuzhou Hospital for Infectious Diseases, Xuzhou, Jiangsu, China.
Hua LiDepartment of Tuberculosis, Linfen 3rd People's Hospital, Linfen, Shanxi, China.
Juan LiDepartment of TB Control, Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, Nangning, China.
Chengqing YangDepartment of Respiratory and Critical Care Medicine of Wuhan Tuberculosis Institute, Wuhan, Hubei, China.
Peng ZhangDepartment of Tuberculosis, 4th Hospital of Tangshan City, Tangshan, Hebei, China.
Hongzhe CuiDepartment of Tuberculosis Control, Yanbian Institute of Tuberculosis Prevention and Control, Yanbian, Jilin, China.
Yuhong LiuDepartment of Tuberculosis, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Chengcheng KongTranslational Medicine Center, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Zhaogang SunTranslational Medicine Center, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Jian DuDepartment of Tuberculosis, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Weiwei GaoDepartment of Tuberculosis, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Beijing Chest Hospital · CNCapital Medical University · CNBeijing Geriatric Hospital · CNCenter for Tuberculosis Control of Guangdong Province · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNChinese Center For Disease Control and Prevention · CNHenan Provincial Center for Disease Control and Prevention · CNShenyang 242 Hospital · CNZunyi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and objective: Retreatment pulmonary tuberculosis (PTB) still accounts for a large proportion of tuberculosis, and the treatment outcome is unfavorable. The recurrence of retreatment PTB based on long-term follow-up has not been well demonstrated. This study aimed to evaluate effect of a modified regimen on drug-sensitive retreated pulmonary tuberculosis. Methods: This multicenter cohort study was conducted in 29 hospitals from 23 regions of China from July 1, 2009, to December 31, 2020. Patients were divided into two treatment regimen groups including experimental group [modified regimen (4H-Rt2-E-Z-S(Lfx)/4H-Rt2-E)]and control group [standard regimen (2H-R-E-Z-S/6H-R-E or 3H-R-E-Z/6H-R-E)]. The patients enrolled were followed up of 56 months after successful treatment. We compared the treatment success rate, treatment failure rate, adverse reaction rate, and recurrence rate between two regimens. Multivariate Cox regression model was used to identify the potential risk factors for recurrence after successful treatment with proportional hazards assumptions tested for all variables. Results: A total of 381 patients with retreatment PTB were enrolled, including 244 (64.0%) in the experimental group and 137 (36.0%) in the control group. Overall, the treatment success rate was significant higher in the experimental group than control group (84.0 vs. 74.5%, Conclusion: The modified retreatment regimen had more favorable treatment effects, including higher treatment success rate and lower recurrence rate in patients with retreated drug-sensitive PTB.

Indexed as

Antitubercular AgentsTuberculosis, PulmonaryChinaCohort StudiesHumansTreatment OutcomeAntitubercular Agentsfollow-upmodified regimenpulmonary tuberculosisrecurrenceretreatment

Identifiers

PMID36778546
PMCPMC9909400
OpenAlexW4318066233

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.